Café

© 2026 Longbridge｜Terms of Service Privacy Policy

CERO

CERO

0.00973.00%( -0.0003 )

LongbridgeAI

Cereno Scientific Reports Favorable Safety and Tolerability after 12 Months of CS1 Treatment in PAH from the Expanded Access Program | B Stock News

StockTitan

Mar 30, 2026 at 06:15 PM

Cereno Scientific Reports Favorable Safety and Tolerability after 12 Months of CS1 Treatment in PAH from the Expanded Access Program | B Stock News

Cereno Scientific Reports Favorable Safety and Tolerability after 12 Months of CS1 Treatment in PAH from the Expanded Access Program | B Stock News

Login to unlock147characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Related Stocks

CERo Therapeutics

USCERO

-3.00%

VanEck Biotech ETF

USBBH

Invesco Nasdaq Biotechnology ETF

USIBBQ